Tirzepatide emerges a groundbreaking pharmaceutical agent for individuals facing type 2 diabetes. As a dual receptor activator, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, resulting in synergistic effects on blood glucose control. By enhancing insulin secretion and reducing g